Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $117.30.

A number of research analysts have commented on the company. HC Wainwright upped their price objective on Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a report on Monday, March 9th. Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $63.00 to $123.00 in a report on Tuesday, March 10th. William Blair reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Wedbush upped their price target on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Finally, Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a research report on Monday, March 9th.

Dianthus Therapeutics Stock Down 2.8%

Shares of DNTH stock opened at $77.76 on Friday. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $88.02. The company has a market capitalization of $3.46 billion, a PE ratio of -18.97 and a beta of 1.56. The firm has a 50 day moving average price of $56.65 and a two-hundred day moving average price of $44.60.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. As a group, research analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $10,016,587.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 33,830 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total value of $2,756,468.40. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 200,430 shares of company stock worth $16,332,702 in the last quarter. Corporate insiders own 8.15% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust grew its holdings in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics during the fourth quarter worth about $40,000. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics during the second quarter worth about $27,000. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Finally, Royal Bank of Canada raised its position in shares of Dianthus Therapeutics by 36.9% in the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after buying an additional 542 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.